[Secondary immune deficiency in renal failure exemplified by hepatitis B vaccination].
In dialysis patients the immune response to hepatitis B-vaccination is greatly impaired. In vitro the non-responders show a failure of the monocytes to support the process of primary T-cell activation. This defect results in a lack of interleukin 2-production and an enhanced sensitivity of the interleukin-2 receptor system. Addition of low doses of interleukin-2 fully reconstitutes the deficient immune response in vitro. Furthermore, the local application of low dose interleukin-2 during a standard vaccination with 40 micrograms hepatitis B-vaccine normalizes the non-responder state in vivo.
Köhler
H
H
I. Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universität Mainz.
Dumann
H
H
Meyer zum Büschenfelde
K H
KH
Meuer
S
S
D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D017325:Hepatitis B Vaccines; D006801:Humans; D007108:Immune Tolerance; D007153:Immunologic Deficiency Syndromes / Q000276:immunology*; D007676:Kidney Failure, Chronic / Q000276:immunology*; D006435:Renal Dialysis; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines
Sekundärer Immundefekt bei Niereninsuffizienz am Beispiel der Hepatitis B-Impfung.